ChemicalBook > Product Catalog >API >Circulatory system drugs >Antihypertensive drugs >Riociguat

Riociguat

Riociguat Suppliers list
Company Name: Jiaxing Novartis Chemical Co., Ltd.  Gold
Tel:18957373295
Email:sales@novamedicals.com
Products Intro:CAS:625115-55-1
Company Name: Hubei Widely Chemical Technology Co., Ltd.  Gold
Tel:027-51119224 18602735115
Email:18602735115@163.com
Products Intro:Product Name:Riociguat
CAS:625115-55-1
Purity:0.99 Package:1G;50G;1KG;5KG
Company Name: SPIRO PHARMA  Gold
Tel:-
Email:eric_feng1954@126.com
Products Intro:Product Name:Riociguat
CAS:625115-55-1
Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
Company Name: Chemwill Asia Co.,Ltd.  Gold
Tel:86-21-51086038
Email:sales@chemwill.com
Products Intro:Product Name:Riociguat
CAS:625115-55-1
Purity:99% Package:Package available of 50gram;500gram,1KG Delivery within 2days Remarks:We have in stock now.
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Tel:86-15221043597
Email:sales@boylechem.com
Products Intro:Product Name:Riociguat
CAS:625115-55-1
Riociguat Basic information
Pharmacological effects Clinical evaluation Production Method Patent cases
Product Name:Riociguat
Synonyms:Riociguat;N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester;Bay 63-2521;Carbamic acid, (4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-B)pyridin-3-yl)-5-pyrimidinyl)methyl-, methyl ester;Riociguat (BAY 63-2521);Bay63-2521,Riociguat;[4,6-DiaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]MethylcarbaMic acid Methyl ester;Methyl (4,6-diaMino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyriMidin-5-yl)(Methyl)carbaMate
CAS:625115-55-1
MF:C20H19FN8O2
MW:422.4156632
EINECS:
Product Categories:API
Mol File:625115-55-1.mol
Riociguat Structure
Riociguat Chemical Properties
density 1.51
Safety Information
MSDS Information
Riociguat Usage And Synthesis
Pharmacological effectsRiociguat is a soluble guanylyl cyclase activator, developed by the German Bayer ,it is an important signaling enzyme, which can be activated by nitric oxide (NO) to catalyze guanosine triphosphate ( GTP) to convert into the second messenger cyclic guanosine monophosphate (cGMP). Soluble guanylate cyclase is currently the only known NO receptor. Damage of NO-sGC-cGMP signal pathway is believed to be the cause of the incidence of cardiovascular, lung, endothelium, kidney and liver diseases. NO synthesis in patients with pulmonary hypertension is not enough, NO donor drugs, although effective, short half-life, riociguat can directly activate sGC, stable NO-sGC combination so as to upregulate the second messenger cGMP. riociquat can significantly increase exercise tolerance in patients with hemodynamic parameters of cardiac function and prolong the time to reach clinical worsening (PATENT study), It may also be effective in treating CTEPH(CHEST study) .
October 8, 2013, the US FDA approved Riociguat for the treatment of chronic thromboembolic pulmonary hypertension and PAH (Pulmonary Arterial Hypertension).
At present, Riociguat is not yet sold in the domestic market ,in the United States it is sold by the Haoeyou Pharmacy , the pharmacy is subsidiary of California Healthcom Group, because the market ofRiociguat is in its infancy, its sales grow slowly.
Clinical evaluationIn clinical trials ,261 patients with chronic thromboembolic pulmonary hypertension (CTEPH) were divided into riociguat and placebo groups, a six-minute walk distance (6MWD) as the main clinical endpoint, after 16 weeks of treatment, 6MWD of riociguat group increased by 46 meters higher than the average in the placebo group. 443 cases of PAH were divided into riociguat and placebo groups,after 12 weeks of treatment, riociguat group increased 36 meters higher than the average 6MWD in the placebo group. Boxed warning suggests that the drug has a embryo toxicity, pregnant patients are forbidden.
Adempas is granted baseing on two global III studies CHEST-1 and PATENT-1, whose findings are published in the July 25, 2013"New England Journal of Medicine," (2013; 369: 330-40; 2013; 369: 319-29). Thomson Reuters released analysis report that it is expected that sales of the drug in 2017 will reach $ 679 million, while the market will face a potential threat constituted by the Swiss company Actelion bosentan and Gilead drug Imber bosentan tablets.
The above information is edited by the chemicalbook of Tian Ye.
Production MethodSynthetic key of Riociguat is the synthesis of three heterocyclic ring. Compounds 1 and 2 directly close the pyrazole ring to generate 3,3 and 4 and then close the pyrazole ring to obtain5, ethyl of 5 is dehydrated using trifluoroacetic anhydride to give a cyano group after amidation by the ammonia , the cyano group is treated with methanol sodium and chloride ammonium to get amidine 6. The two nitrogen atoms on Amidine 6 as dinucleophile, with two cyano on compound 7 as the electrophile ,directly close the pyrimidine ring to give 8. pyrimidine 5-position amino group on 8 with a strong nucleophilic, directly reacts with methyl chloride and then methylates to give riociguat.
a chemical reactions road map of Riociguat production
Figure 1 is a chemical reactions road map of Riociguat production .
Patent casesUS7173037 (there is a deadline to April 25, 2023), US6743798 (valid until July 16, 2019).
Chemical PropertiesBrownish Orange Solid
UsesRiocguat is used in the treatment for pulmonary hypertension.
DefinitionChEBI: A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension an pulmonary arterial hypertension
Riociguat Preparation Products And Raw materials
Tag:Riociguat(625115-55-1) Related Product Information
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)- 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine 1-(2-Fluoro-benzyl)-1H-py... Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate